Agape ATP Corp

Agape ATP Corp(ATPC)股票分析

$1.370

+0.131 (+9.59%)收盤時

Loading chart…
最高
1.425
開盤
1.320
成交量加權均價
1.36
成交量
12.22K
市值
—
最低
1.280
成交金額
16.60K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual.

AI 分析 of Agape ATP Corp (ATPC)

賣出

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

估值指標

Agape ATP Corp(ATPC)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 ATPC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ATPC

$1.53

情境價格

基

基準

基準 · 50%ATPC

$1.40

情境價格

悲

悲觀

悲觀 · 25%ATPC

$1.25

情境價格

事件時間軸

2026-03-12 (ET)

09:20:00

Agape ATP Regains Nasdaq Listing Compliance

2026-03-10 (ET)

09:30:00

AGAPE ATP Enters Collaboration Agreement with Citadel Investment

2026-02-09 (ET)

20:00:00

Agape ATP Corp Trading Halted, News Pending

2026-02-06 (ET)

13:40:00

Agape ATP Files $200M Mixed Securities Shelf

2026-02-05 (ET)

09:10:00

Agape ATP Corporation Faces Potential Nasdaq Delisting

資訊

ATPC 常見問題 —— 由 Alphio AI 解答

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual. It operates in the Healthcare sector.

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易